Prof Anton Hagenbeek at ASH 2014: Brentuximab vedotin therapy for Hodgkin lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the investigational approaches of brentuximab vedotin, an anti-CD30 antibody conjugated to a cytostatic microtubule-disrupting agent, in the treatment of previously untreated and refractory/relapse patients with Hodgkin lymphoma.